Copyright Reports & Markets. All rights reserved.

Global Predictive Presymptomatic Testing Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered: Ranking by Predictive Presymptomatic Testing Revenue
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Predictive Presymptomatic Testing Market Size Growth Rate by Type: 2020 VS 2026
      • 1.4.2 Molecular Testing
      • 1.4.3 Cytogenic Testing
      • 1.4.4 Biochemical Testing
    • 1.5 Market by Application
      • 1.5.1 Global Predictive Presymptomatic Testing Market Share by Application: 2020 VS 2026
      • 1.5.2 Breast and Ovarian Cancer
      • 1.5.3 Colorectal Cancer
      • 1.5.4 Alzheimer's Disease
      • 1.5.5 Multiple Endocrine Neoplasia Type 2
      • 1.5.6 Haemochromatosis
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends by Regions

    • 2.1 Predictive Presymptomatic Testing Market Perspective (2015-2026)
    • 2.2 Predictive Presymptomatic Testing Growth Trends by Regions
      • 2.2.1 Predictive Presymptomatic Testing Market Size by Regions: 2015 VS 2020 VS 2026
      • 2.2.2 Predictive Presymptomatic Testing Historic Market Share by Regions (2015-2020)
      • 2.2.3 Predictive Presymptomatic Testing Forecasted Market Size by Regions (2021-2026)
    • 2.3 Industry Trends and Growth Strategy
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis
      • 2.3.5 Predictive Presymptomatic Testing Market Growth Strategy
      • 2.3.6 Primary Interviews with Key Predictive Presymptomatic Testing Players (Opinion Leaders)

    3 Competition Landscape by Key Players

    • 3.1 Global Top Predictive Presymptomatic Testing Players by Market Size
      • 3.1.1 Global Top Predictive Presymptomatic Testing Players by Revenue (2015-2020)
      • 3.1.2 Global Predictive Presymptomatic Testing Revenue Market Share by Players (2015-2020)
      • 3.1.3 Global Predictive Presymptomatic Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.2 Global Predictive Presymptomatic Testing Market Concentration Ratio
      • 3.2.1 Global Predictive Presymptomatic Testing Market Concentration Ratio (CR5 and HHI)
      • 3.2.2 Global Top 10 and Top 5 Companies by Predictive Presymptomatic Testing Revenue in 2019
    • 3.3 Predictive Presymptomatic Testing Key Players Head office and Area Served
    • 3.4 Key Players Predictive Presymptomatic Testing Product Solution and Service
    • 3.5 Date of Enter into Predictive Presymptomatic Testing Market
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type (2015-2026)

    • 4.1 Global Predictive Presymptomatic Testing Historic Market Size by Type (2015-2020)
    • 4.2 Global Predictive Presymptomatic Testing Forecasted Market Size by Type (2021-2026)

    5 Predictive Presymptomatic Testing Breakdown Data by Application (2015-2026)

    • 5.1 Global Predictive Presymptomatic Testing Market Size by Application (2015-2020)
    • 5.2 Global Predictive Presymptomatic Testing Forecasted Market Size by Application (2021-2026)

    6 North America

    • 6.1 North America Predictive Presymptomatic Testing Market Size (2015-2020)
    • 6.2 Predictive Presymptomatic Testing Key Players in North America (2019-2020)
    • 6.3 North America Predictive Presymptomatic Testing Market Size by Type (2015-2020)
    • 6.4 North America Predictive Presymptomatic Testing Market Size by Application (2015-2020)

    7 Europe

    • 7.1 Europe Predictive Presymptomatic Testing Market Size (2015-2020)
    • 7.2 Predictive Presymptomatic Testing Key Players in Europe (2019-2020)
    • 7.3 Europe Predictive Presymptomatic Testing Market Size by Type (2015-2020)
    • 7.4 Europe Predictive Presymptomatic Testing Market Size by Application (2015-2020)

    (2015-2020)

      (2015-2020)

        (2015-2020)

          (2015-2020)

            8 Key Players Profiles

            • 8.1 23andMe, Inc.
              • 8.1.1 23andMe, Inc. Company Details
              • 8.1.2 23andMe, Inc. Business Overview and Its Total Revenue
              • 8.1.3 23andMe, Inc. Predictive Presymptomatic Testing Introduction
              • 8.1.4 23andMe, Inc. Revenue in Predictive Presymptomatic Testing Business (2015-2020))
              • 8.1.5 23andMe, Inc. Recent Development
            • 8.2 Abbott Laboratories
              • 8.2.1 Abbott Laboratories Company Details
              • 8.2.2 Abbott Laboratories Business Overview and Its Total Revenue
              • 8.2.3 Abbott Laboratories Predictive Presymptomatic Testing Introduction
              • 8.2.4 Abbott Laboratories Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.2.5 Abbott Laboratories Recent Development
            • 8.3 Bayer HealthCare AG
              • 8.3.1 Bayer HealthCare AG Company Details
              • 8.3.2 Bayer HealthCare AG Business Overview and Its Total Revenue
              • 8.3.3 Bayer HealthCare AG Predictive Presymptomatic Testing Introduction
              • 8.3.4 Bayer HealthCare AG Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.3.5 Bayer HealthCare AG Recent Development
            • 8.4 Biocartis SA
              • 8.4.1 Biocartis SA Company Details
              • 8.4.2 Biocartis SA Business Overview and Its Total Revenue
              • 8.4.3 Biocartis SA Predictive Presymptomatic Testing Introduction
              • 8.4.4 Biocartis SA Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.4.5 Biocartis SA Recent Development
            • 8.5 BioHelix Corporation
              • 8.5.1 BioHelix Corporation Company Details
              • 8.5.2 BioHelix Corporation Business Overview and Its Total Revenue
              • 8.5.3 BioHelix Corporation Predictive Presymptomatic Testing Introduction
              • 8.5.4 BioHelix Corporation Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.5.5 BioHelix Corporation Recent Development
            • 8.6 bioMerieux S.A.
              • 8.6.1 bioMerieux S.A. Company Details
              • 8.6.2 bioMerieux S.A. Business Overview and Its Total Revenue
              • 8.6.3 bioMerieux S.A. Predictive Presymptomatic Testing Introduction
              • 8.6.4 bioMerieux S.A. Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.6.5 bioMerieux S.A. Recent Development
            • 8.7 Celera Corporation (Quest Diagnostics)
              • 8.7.1 Celera Corporation (Quest Diagnostics) Company Details
              • 8.7.2 Celera Corporation (Quest Diagnostics) Business Overview and Its Total Revenue
              • 8.7.3 Celera Corporation (Quest Diagnostics) Predictive Presymptomatic Testing Introduction
              • 8.7.4 Celera Corporation (Quest Diagnostics) Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.7.5 Celera Corporation (Quest Diagnostics) Recent Development
            • 8.8 Cepheid (Danaher)
              • 8.8.1 Cepheid (Danaher) Company Details
              • 8.8.2 Cepheid (Danaher) Business Overview and Its Total Revenue
              • 8.8.3 Cepheid (Danaher) Predictive Presymptomatic Testing Introduction
              • 8.8.4 Cepheid (Danaher) Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.8.5 Cepheid (Danaher) Recent Development
            • 8.9 Daan Diagnostics Ltd.
              • 8.9.1 Daan Diagnostics Ltd. Company Details
              • 8.9.2 Daan Diagnostics Ltd. Business Overview and Its Total Revenue
              • 8.9.3 Daan Diagnostics Ltd. Predictive Presymptomatic Testing Introduction
              • 8.9.4 Daan Diagnostics Ltd. Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.9.5 Daan Diagnostics Ltd. Recent Development
            • 8.10 EKF Diagnostics Holdings plc
              • 8.10.1 EKF Diagnostics Holdings plc Company Details
              • 8.10.2 EKF Diagnostics Holdings plc Business Overview and Its Total Revenue
              • 8.10.3 EKF Diagnostics Holdings plc Predictive Presymptomatic Testing Introduction
              • 8.10.4 EKF Diagnostics Holdings plc Revenue in Predictive Presymptomatic Testing Business (2015-2020)
              • 8.10.5 EKF Diagnostics Holdings plc Recent Development

            9 Analyst's Viewpoints/Conclusions

              10 Appendix

              • 10.1 Research Methodology
                • 10.1.1 Methodology/Research Approach
                • 10.1.2 Data Source
              • 10.2 Disclaimer

              This report focuses on the global Predictive Presymptomatic Testing status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Predictive Presymptomatic Testing development in North America and Europe..

              The key players covered in this study
              23andMe, Inc.
              Abbott Laboratories
              Bayer HealthCare AG
              Biocartis SA
              BioHelix Corporation
              bioMerieux S.A.
              Celera Corporation (Quest Diagnostics)
              Cepheid (Danaher)
              Daan Diagnostics Ltd.
              EKF Diagnostics Holdings plc

              Market segment by Type, the product can be split into
              Molecular Testing
              Cytogenic Testing
              Biochemical Testing
              Market segment by Application, split into
              Breast and Ovarian Cancer
              Colorectal Cancer
              Alzheimer's Disease
              Multiple Endocrine Neoplasia Type 2
              Haemochromatosis

              Market segment by Regions/Countries, this report covers
              North America
              Europe

              The study objectives of this report are:
              To analyze global Predictive Presymptomatic Testing status, future forecast, growth opportunity, key market and key players.
              To present the Predictive Presymptomatic Testing development in North America and Europe..
              To strategically profile the key players and comprehensively analyze their development plan and strategies.
              To define, describe and forecast the market by type, market and key regions.

              In this study, the years considered to estimate the market size of Predictive Presymptomatic Testing are as follows:
              History Year: 2015-2019
              Base Year: 2019
              Estimated Year: 2020
              Forecast Year 2020 to 2026
              For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
              Buy now